Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orlistat + pioglitazone/metformin vs pioglitazone/metformin in obese type 2 diabetes mellitus
ChiCTR2200059191Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of orlistat, pioglitazone and metformin in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: HbA1c, height and 7 more. Started Apr 2022; status: recruiting.
02
Drugs
orlistatpioglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2200059191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059191.